Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The Phase 1 study of prulacabtagene leucl (prula-cel) in systemic lupus erythematosus with or without lupus nephritis showed no CRS above Grade 2, no ICANS and no IEC-HS. At 12 months, 54% of evaluable patients achieved DORIS remission and 50% achieved complete renal response.
Adicet Bio said it will host a webcast to present clinical data for prula-cel, formerly ADI-001, in patients with systemic lupus erythematosus with or without lupus nephritis.
For best results when printing this announcement, please click on link below: Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Ph…